AnaSpec, In Vitro Ink Distribution Deal | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – AnaSpec has reached a non-exclusive distribution deal with In Vitro covering a broad spectrum of AnaSpec products in Europe, the two companies and Eurogentec Group, AnaSpec's parent company, announced on Wednesday.

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.